Carisma Therapeutics Announces Participation in Key Conferences
Carisma Therapeutics' Upcoming Conference Presentations
Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company pioneering innovative immunotherapies, is set to present at several prominent conferences in the near future. With Steven Kelly, the President and CEO, leading the discussions, these events aim to share Carisma's groundbreaking research and developments in the field of immunotherapy.
Key Conference Details
Baird 2024 Global Healthcare Conference
Scheduled for Tuesday, September 10, at 12:50 PM ET, this conference will take place in New York and serves as an ideal platform for Carisma to engage with stakeholders and showcase its advancements.
H.C. Wainwright 26th Annual Global Investment Conference
On Wednesday, September 11, Carisma will take the stage at 1:30 PM ET in New York, providing insights into its ongoing projects and strategic direction.
Chardan's 8th Annual Genetic Medicines Conference
This conference is set for Monday, September 30, with Carisma presenting at 4:00 PM ET in New York. The focus will be on the company’s innovative approaches in genetic medicine and immunotherapy.
The Cell & Gene Meeting on the Mesa
Taking place on Monday, October 7, at 9:30 AM MST in Phoenix, Arizona, this meeting represents a significant opportunity for Carisma to connect with key industry leaders and discuss its unique therapeutic strategies.
Accessing Conference Webcasts
For those unable to attend in person, live webcasts of the presentations will be available on Carisma's Investor Events page. Furthermore, a replay of these webcasts will be archived for a limited period after each event, ensuring that interested parties can catch up on the discussions at their convenience.
About Carisma Therapeutics
Founded to transform the landscape of cancer treatment, Carisma Therapeutics Inc. is focused on utilizing a proprietary cell engineering platform to develop cutting-edge immunotherapies. Their unique approach harnesses the power of engineered macrophages and monocytes to advance immune response mechanisms, addressing serious diseases with innovative therapies. For additional details about the company and its mission, please visit www.carismatx.com.
Contact Information
Investors
Shveta Dighe
Head of Investor Relations
[email protected]
Media Contact
Julia Stern
(763) 350-5223
[email protected]
Frequently Asked Questions
What is Carisma Therapeutics focused on?
Carisma Therapeutics is dedicated to developing innovative immunotherapies to treat cancer and other serious diseases using their proprietary cell therapy platform.
Who will represent Carisma at the upcoming conferences?
Steven Kelly, the President and CEO of Carisma Therapeutics, will represent the company at these conferences.
When will the Baird 2024 Global Healthcare Conference take place?
The Baird 2024 Global Healthcare Conference is scheduled for September 10, 2024, at 12:50 PM ET in New York.
How can I access the conference webcasts?
The webcasts will be available on Carisma's Investor Events webpage during the events and will be archived for a limited time after.
Where can I find more information about Carisma Therapeutics?
For further details, you can visit Carisma Therapeutics' official website at www.carismatx.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Lerner Publishing Group Expands Portfolio with New Acquisition
- Understanding Nexans S.A. Share Capital and Voting Rights
- Cyclacel Pharmaceuticals Pursues Hearing After Delisting Notice
- EzFill Holdings, Inc. Achieves NASDAQ Listing Compliance Again
- SS Innovations' First Mantra Surgical System Sale in Latin America
- Yukon Metals Unveils Promising Gold and Copper Discovery
- Constellation Brands Revises Fiscal 2025 Financial Outlook
- Polarean Imaging Welcomes Alan Huang as VP of Sales
- Coloplast A/S Share Trading Insights for Board and Executives
- RecycLiCo Battery Materials Appoints Dr. Maryam Rasouli as Principal Engineer
- Procaps Group Outlines Strategic Vision for Future Success
- GLOBO Language Solutions Explores AI in Medical Interpretation
- DemandScience Achieves a Historic 11th Inc. 5000 Honor
- Object Management Group Launches New Journal of Innovation
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
- Sustainable Apparel Market Projected to Hit USD 24.53 Billion
- Bio-Based Coatings Market Growth Driven by Eco-Friendly Demand
- Optical Modulators Market Growth Metrics and Key Drivers
- The Surging Mixed Reality Market: Predicted to Hit USD 76.91 Billion
- Global Cash Handling Device Market Growth Insights
- Affiliated Network Providers and Aurora Health Join Forces
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- Johnny Clark Welcomes EFFO: The Ultimate Frying Oil Solution
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
Recent Articles
- Johnny Clark Welcomes EFFO: The Ultimate Frying Oil Solution
- Spectral Capital Launches NOOT: A Revolutionary Quantum Social Media
- DriveItAway Partners with AllShifts to Support Nurses' Mobility
- Avadel Pharmaceuticals Reveals Strong Preference for LUMRYZ™
- Denali Therapeutics Plans Accelerated Approval for DNL310
- Kevin Guest's Insights on the Power of Entrepreneurs Today
- PharmaCorp Strengthens Position with New Pharmacy Acquisition
- Carisma Therapeutics Announces Participation in Key Conferences
- Video Conferencing Solutions Market to Hit $49.7 Billion by 2032
- Invivyd's PEMGARDA™ Effectiveness Against SARS-CoV-2 Variants
- Oruka Therapeutics Completes Merger with ARCA Biopharma
- JinkoSolar Provides Over 1,000 Solar Modules for Relief
- Aviation Safety Summit 2024: Leaders In Safety Innovations
- Blackwell 3D Advances Corporate Growth and Asian Expansion Plans
- Prime Mining Corp Reports High-Grade Drilling Expansion
- Gold Prices Drop as US Dollar Strengthens; Euro Surges
- Investing Insights: Top Picks from Warren Buffett's Portfolio
- Agmatix Unveils RegenIQ: Revolutionizing Regenerative Agriculture
- Big-Box Retailers Poised to Displace Dollar General Market
- Plant-Based Meat Market Growth Expected to Reach $31.7 Billion
- SeeByte and Kraken Robotics Collaborate for Integrated Solutions
- Essential Details on Riksbank Certificates Auction 2024
- Iridium Network: First to Use RayCare and TrueBeam Together
- Silver Cross and Lamborghini Team Up for Luxury Stroller
- China-Africa Cooperation: Paving the Way for Modernization